https://www.epo.org/fr/boards-of-appeal/decisions/t140517eu1
T 0517/14 (Ibandronate sodium, Form T/TEVA) du 19.06.2015
ibandronate sodium19 06051714
https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1523207/full
Frontiers | Case series: Chemical pneumonitis caused by exposure of sodium ibandronate powder
This report presents two cases of chemical pneumonitis caused by the exposure of sodium ibandronate powder, a bisphosphonate used for treating osteoporosis. ...
case serieschemical pneumonitis